AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Syndax Pharmaceuticals In... (SNDX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.23

-0.13 (-0.91%)

At close: Jan 29, 2025, 3:59 PM

14.24

0.04%

After-hours Jan 29, 2025, 04:00 PM EST

undefined% (undefined)

Bid	13.63
Market Cap	1.22B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.64
PE Ratio (ttm)	-3.91
Forward PE	n/a
Analyst	Buy

Ask	14.5
Volume	1,379,962
Avg. Volume (20D)	2,360,610
Open	14.28
Previous Close	14.36
Day's Range	14.07 - 14.56
52-Week Range	12.06 - 25.34
Beta	undefined

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 2, 2016

Employees 184

Stock Exchange NASDAQ

Ticker Symbol SNDX

Website https://www.syndax.com

Analyst Forecast

According to 10 analyst ratings, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 159.92% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Syndax Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $21.98M, reflecting a n/a YoY growth and earnings per share of -1.07, making a 7.00% increase YoY.

Why Price Moved

2 months ago

-25.57%

Syndax Pharmaceuticals shares are trading lower. T... Unlock content with Pro Subscription

6 months ago

-10.21%

Syndax Pharmaceuticals shares are trading lower after the FDA extended the review period for the company's leukemia drug Revumenib.

News

2 months ago · reuters.com

US FDA approves Syndax's blood cancer drug

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% ...

2 months ago · seekingalpha.com

Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity

Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action da...

2 months ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive...

2 months ago · zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago.